Stem cells as a promising therapeutic direction for the treatment of serious diseases

T. Sprynsian
{"title":"Stem cells as a promising therapeutic direction for the treatment of serious diseases","authors":"T. Sprynsian","doi":"10.32902/2663-0338-2021-2-5-10","DOIUrl":null,"url":null,"abstract":"ABSTRACT. Stem cells have attracted scientific, clinical and public interest because they can regenerate and develop in certain types of cells, depending on their source of origin and biological plasticity. Several strategies for the use of cell therapy are currently being explored. A total of 8357 clinical trials of various stages using stem cells have been registered. The possibility of using multipotent mesenchymal stromal cells in patients with COVID-19-induced complications is being actively investigated. However, among the stem cell products, the U.S. Food and Drug Administration (FDA) has so far approved only those that are produced from umbilical cord blood. In the USA and European countries, there are private clinics that provide services for the collection and cultivation of stem cells, mainly autologous. Such medical centers can become the point of concentration of personalized medicine, focused on the needs of a particular patient and his/her possibilities of receiving targeted therapy for severe, difficult-to-treat conditions using modern methods in cellular technologies. The article presents an analysis of existing strategies for the therapeutic use of stem cells and the most promising directions for their further study.","PeriodicalId":13681,"journal":{"name":"Infusion & Chemotherapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infusion & Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32902/2663-0338-2021-2-5-10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

ABSTRACT. Stem cells have attracted scientific, clinical and public interest because they can regenerate and develop in certain types of cells, depending on their source of origin and biological plasticity. Several strategies for the use of cell therapy are currently being explored. A total of 8357 clinical trials of various stages using stem cells have been registered. The possibility of using multipotent mesenchymal stromal cells in patients with COVID-19-induced complications is being actively investigated. However, among the stem cell products, the U.S. Food and Drug Administration (FDA) has so far approved only those that are produced from umbilical cord blood. In the USA and European countries, there are private clinics that provide services for the collection and cultivation of stem cells, mainly autologous. Such medical centers can become the point of concentration of personalized medicine, focused on the needs of a particular patient and his/her possibilities of receiving targeted therapy for severe, difficult-to-treat conditions using modern methods in cellular technologies. The article presents an analysis of existing strategies for the therapeutic use of stem cells and the most promising directions for their further study.
干细胞作为治疗重大疾病的一个有前景的治疗方向
摘要干细胞吸引了科学、临床和公众的兴趣,因为它们可以在某些类型的细胞中再生和发育,这取决于它们的来源和生物可塑性。目前正在探索几种使用细胞疗法的策略。共有8357个使用干细胞的不同阶段的临床试验已经注册。正在积极研究在新冠肺炎并发症患者中使用多能间充质基质细胞的可能性。但是,在干细胞产品中,美国食品药品监督管理局(FDA)迄今只批准了脐带血生产的干细胞产品。在美国和欧洲国家,有私人诊所提供干细胞的收集和培养服务,主要是自体干细胞。这样的医疗中心可以成为个性化医疗的集中点,专注于特定患者的需求,以及他/她使用现代细胞技术方法接受严重的、难以治疗的疾病的靶向治疗的可能性。本文对干细胞治疗的现有策略进行了分析,并对其进一步研究的前景进行了展望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信